Business Wire

MA-ONAPSIS

10.5.2022 15:02:13 CEST | Business Wire | Press release

Share
Onapsis Announces New Offering to Jumpstart Security for SAP Customers

Onapsis , the leader in business-critical application cybersecurity and compliance, today announced the release of Onapsis Assess Baseline. In a world where business-critical applications are under attack every day, this new offering accelerates organizations’ abilities to kickstart their SAP vulnerability management programs by better aligning with the SAP Security Baseline.

The exponential growth of targeted ransomware and the increased threat of cyber warfare due to global conflict means that organizations must re-evaluate how they secure their most critical systems. Amid this evolving, more aggressive threat landscape , companies struggle to keep up with patching the growing number of vulnerabilities exploited by threat actors to gain access to their business-critical applications. Onapsis Assess Baseline empowers companies of any size to accelerate time-to-value by simplifying deployment with a new SaaS-based, zero-footprint model and focusing on a core, targeted set of critical vulnerabilities as first steps on their journey to ensure cybersecurity, compliance, and availability of their SAP applications. When organizations are ready to take on more, Onapsis Assess Baseline offers easy expansion to additional scope for vulnerability management as well as capabilities for continuous threat monitoring and application security testing.

Key Organizational Benefits with Onapsis Assess Baseline:

  • Reduce Implementation Overhead with an Accelerated Deployment: Whether in their own cloud, on-premises, or through Onapsis’ SaaS platform, Assess Baseline offers quick deployment and implementation with zero footprint scanning.
  • Accelerate Time-to-Value for SAP Vulnerability Management: Onapsis SaaS users can scan with Assess Baseline against the SAP-recommended security baseline requirements for an organization’s SAP systems within hours. The scans deliver powerful context around critical vulnerabilities, instructions on how to mitigate, and confidence that patches were applied, saving valuable resource time.
  • Technology that Scales and Grows When You’re Ready: Deploy where you want. Scan across the entire SAP landscape. Start small and target the most critical systems first, get them aligned to a baseline, and then expand the security scope across the organization on your terms.

“Securing business-critical applications has always been challenging, but there’s a larger bullseye on the backs of organizations today - more than ever before - as sophisticated threat actors increasingly target Enterprise Resource Planning (ERP) systems,” said Mariano Nunez, CEO of Onapsis. “We have successfully helped the world’s largest and most sophisticated organizations integrate their business applications into their cybersecurity and compliance programs. Now, Assess Baseline makes it easy for customers who are getting started with their SAP application security programs to quickly and effectively jumpstart protecting the applications that power their businesses.”

The Onapsis Platform secures the critical SAP applications that keep the global economy running. The platform is purpose-built to deliver impactful vulnerability management, advanced threat detection, custom code inspection, and automated compliance that enables global organizations to accelerate their business and digital transformation initiatives. The Onapsis Platform is deeply informed by the latest threat intelligence and security guidance from the Onapsis Research Labs. This market-leading team has discovered more than 800 zero-day vulnerabilities and is responsible for multiple critical global CERT alerts.

“Today’s threat landscape requires a holistic approach to securing business-critical SAP applications such as ERP software,” said Steve Biskie, national ERP risk and automation services leader with RSM US LLP. “It is exciting to see Onapsis continuing to innovate its solutions to assist companies on their security maturity journey. The new Baseline license can help pave the way for more organizations to have an entry point into vulnerability management for SAP applications that could help keep their critical data and applications safe and compliant.”

Attending the SAP Sapphire conference? Visit the Onapsis booth to learn more: #PA219

To schedule a time to speak with an Onapsis expert while at Sapphire, please visit: https://onapsis.com/sapphire-22

About Onapsis

Onapsis protects the business-critical applications that run the global economy, from the core to the cloud. The company’s cybersecurity and compliance solution offering, The Onapsis Platform, uniquely delivers vulnerability management, threat detection and response, change assurance, and continuous compliance for business-critical applications from leading vendors such as SAP, Oracle, Salesforce, and other SaaS platforms.

Onapsis is headquartered in Boston, MA, with offices in Heidelberg, Germany and Buenos Aires, Argentina, and proudly serves more than 300 of the world’s leading brands, including 20% of the Fortune 100, 6 of the top 10 automotive companies, 5 of the top 10 chemical companies, 4 of the top 10 technology companies, and 3 of the top 10 oil and gas companies.

The Onapsis Platform is powered by the Onapsis Research Labs, the team responsible for the discovery and mitigation of more than 800 zero-day vulnerabilities in business-critical applications. The reach of our threat research and platform is broadened through leading consulting and audit firms such as Accenture, Deloitte, IBM, PwC, and KPMG — making Onapsis solutions the standard in helping organizations protect their cloud, hybrid, and on-premises business-critical information and processes. For more information, connect with us on Twitter or LinkedIn , or visit us at https://onapsis.com/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye